全文获取类型
收费全文 | 74180篇 |
免费 | 7510篇 |
国内免费 | 2641篇 |
专业分类
耳鼻咽喉 | 174篇 |
儿科学 | 854篇 |
妇产科学 | 434篇 |
基础医学 | 3202篇 |
口腔科学 | 539篇 |
临床医学 | 7034篇 |
内科学 | 9548篇 |
皮肤病学 | 1418篇 |
神经病学 | 2847篇 |
特种医学 | 919篇 |
外国民族医学 | 10篇 |
外科学 | 2763篇 |
综合类 | 9168篇 |
现状与发展 | 7篇 |
一般理论 | 4篇 |
预防医学 | 5193篇 |
眼科学 | 828篇 |
药学 | 31569篇 |
89篇 | |
中国医学 | 3342篇 |
肿瘤学 | 4389篇 |
出版年
2024年 | 167篇 |
2023年 | 1518篇 |
2022年 | 1843篇 |
2021年 | 3207篇 |
2020年 | 3337篇 |
2019年 | 3135篇 |
2018年 | 3013篇 |
2017年 | 3195篇 |
2016年 | 2935篇 |
2015年 | 2904篇 |
2014年 | 5008篇 |
2013年 | 7849篇 |
2012年 | 4840篇 |
2011年 | 4949篇 |
2010年 | 3986篇 |
2009年 | 3494篇 |
2008年 | 3365篇 |
2007年 | 3320篇 |
2006年 | 2930篇 |
2005年 | 2613篇 |
2004年 | 2200篇 |
2003年 | 2049篇 |
2002年 | 1507篇 |
2001年 | 1458篇 |
2000年 | 1129篇 |
1999年 | 950篇 |
1998年 | 838篇 |
1997年 | 787篇 |
1996年 | 667篇 |
1995年 | 613篇 |
1994年 | 518篇 |
1993年 | 454篇 |
1992年 | 508篇 |
1991年 | 458篇 |
1990年 | 356篇 |
1989年 | 277篇 |
1988年 | 283篇 |
1987年 | 281篇 |
1986年 | 221篇 |
1985年 | 218篇 |
1984年 | 178篇 |
1983年 | 132篇 |
1982年 | 119篇 |
1981年 | 101篇 |
1980年 | 61篇 |
1979年 | 61篇 |
1978年 | 70篇 |
1977年 | 52篇 |
1976年 | 52篇 |
1975年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
41.
42.
43.
Co-trimoxazole is mainly used as a first-line drug for treatment and prophylaxis against Pneumocystis jiroveci pneumonia. This drug, however, has been reported as the most common causative drug for severe cutaneous adverse reactions (SCARs). This study aimed to extensively elucidate the associations between genetic polymorphisms of HLA class I and genes involved in bioactivation and detoxification of co-trimoxazole on co-trimoxazole-induced SCARS in a large sample size and well-defined Thai SCARs patients. A total of 67 patients with co-trimoxazole-induced SCARs, consisting of 51 SJS/TEN patients and 16 DRESS patients, and 91 co-trimoxazole tolerant controls were enrolled in the study. The results clearly demonstrated that the HLA-B113:01 allele was significantly associated with co-trimoxazole-induced SCARs, especially with DRESS (OR = 8.44, 95% CI = 2.66–26.77, P = 2.94 × 10−4, Pc = 0.0126). Moreover, the HLA-C108:01 allele was significantly associated with co-trimoxazole-induced SJS/TEN in the HIV/AIDS patients with an OR of 8.51 (95% CI = 2.18–33.14, P = 8.60 × 10−4, Pc = 0.0241). None of the genes involved in the bioactivation and detoxification of co-trimoxazole investigated in this study play any major role in the development of all phenotypes of SCARs. 相似文献
44.
欧洲药品局(EMA)于2018年11月发布了"人用药品辅料右旋糖酐的包装说明书资料",该文件引用大量文献全面评价了右旋糖酐的安全性,特别指出含有右旋糖酐辅料的注射和吸入制剂的疫苗与药品,应在说明书中描述有关其过敏反应信息的新要求。介绍该文件的主要内容,期望对我国这类药品说明书的撰写和监管有所帮助。 相似文献
45.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
46.
Sina Dami 《World Journal of Clinical Cases》2022,10(26):9207-9218
The coronavirus disease 2019 (COVID-19) has currently caused the mortality of millions of people around the world. Aside from the direct mortality from the COVID-19, the indirect effects of the pandemic have also led to an increase in the mortality rate of other non-COVID patients. Evidence indicates that novel COVID-19 pandemic has caused an inflation in acute cardiovascular mortality, which did not relate to COVID-19 infection. It has in fact increased the risk of death in cardiovascular disease (CVD) patients. For this purpose, it is dramatically inevitable to monitor CVD patients’ vital signs and to detect abnormal events before the occurrence of any critical conditions resulted in death. Internet of things (IoT) and health monitoring sensors have improved the medical care systems by enabling latency-sensitive surveillance and computing of large amounts of patients’ data. The major challenge being faced currently in this problem is its limited scalability and late detection of cardiovascular events in IoT-based computing environments. To this end, this paper proposes a novel framework to early detection of cardiovascular events based on a deep learning architecture in IoT environments. Experimental results showed that the proposed method was able to detect cardiovascular events with better performance (95.30% average sensitivity and 95.94% mean prediction values). 相似文献
47.
48.
49.
50.
血吸虫病是一种严重危害人类健康、影响社会经济发展的重大传染病,为全球公共卫生负担和危害最严重的被忽视的热带病之一。吡喹酮是20世纪70年代研制出的一种高效、低毒、价廉的广谱抗蠕虫口服药,为世界卫生组织(WHO)推荐的抗血吸虫的首选药物。吡喹酮在血吸虫病流行区现场大规模反复使用已超过40年,血吸虫是否会对吡喹酮产生抗药性引起国际社会极大担忧,为学术界关注的热点科学问题。针对血吸虫病防治中这一重大需求,自1996年起, 在国家科技支撑计划、国家自然科学基金、江苏省自然科学基金等项目基金资助下,我们在血吸虫病流行区现场和实验室,对血吸虫在吡喹酮药物的压力是否会产生抗药性、抗性虫株的生物学特性、抗性的检测、吡喹酮抗性的交叉抗药性及抗药性的预防和控制等科学问题进行较为系统的研究,本文就其研究及其意义作一概述。 相似文献